NERVGEN PHARMA
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.
NERVGEN PHARMA
Social Links:
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2017-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.nervgen.com
Total Employee:
11+
Status:
Active
Contact:
6047225361
Total Funding:
32.55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics
Similar Organizations
Homology Medicines
Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
PFP Biosciences
PFP Biosciences investment in Post-IPO Equity - NervGen Pharma
CSBio
CSBio investment in Post-IPO Equity - NervGen Pharma
Official Site Inspections
http://www.nervgen.com Semrush global rank: 1.51 M Semrush visits lastest month: 17.75 K
Unable to get host informations!!!
More informations about "NervGen Pharma"
Homepage - NervGen Pharma
Nov 14, 2024 · We create innovative treatments for nervous system damage due to injury or disease. NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company …See details»
About NervGen - NervGen Pharma
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic …See details»
NervGen Pharma to Receive More Than US$3 Million from Wings …
June 27, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for …See details»
NervGen Pharma On Track To Complete Enrollment, Deliver Data …
Feb 15, 2024 · VANCOUVER, BC – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment …See details»
NervGen Pharma - Crunchbase Company Profile & Funding
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, …See details»
NervGen Pharma Corp. - LinkedIn
NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or...See details»
Mike Kelly - President & CEO at NervGen Pharma | The Org
Mike Kelly brings three decades of pharmaceutical experience playing instrumental roles in the creation, development, and strengthening of several companies to his role as President & …See details»
NervGen Pharma Company Description - Stock Analysis
Nov 20, 2024 · It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord …See details»
NervGen Pharma Provides an Operational Update on Its Ongoing …
Aug 19, 2021 · VANCOUVER, BC — Newsfile Corp. — NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated …See details»
NervGen Pharma Announces Intent to Conduct
Jan 10, 2022 · NVG-291 is based on the groundbreaking discovery by Dr. Jerry Silver at Case Western Reserve University of a class of molecules (chondroitin sulfate proteoglycans, or CSPGs) that are...See details»
Enabling the Nervous System to Repair Itself - NervGen Pharma
Sep 28, 2022 · NervGen’s linical Trials are Led by Experienced Drug Developers •25+ years pharma experience and as practicing neurologist conducting clinical research •Joined …See details»
NervGen Pharma on Track to Complete Enrollment, Deliver Data
Feb 15, 2024 · NervGen Pharma Corp., a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it is …See details»
NervGen Pharma Reports Q3 2024 Financial Results and …
Nov 14, 2024 · Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completionNVG-300 preclinical …See details»
NervGen Pharma to Receive More Than US$3 Million From Wings …
Jun 27, 2023 · VANCOUVER, BC — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing …See details»
NervGen Pharma Announces First Subject Dosed in Landmark …
Sep 25, 2023 · Vancouver, British Columbia-- (Newsfile Corp. - September 25, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated …See details»
NervGen Pharma Corp. - YouTube
NervGen Pharma Corp. (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself …See details»
NervGen Pharma Corp. (NGEN.V) - Yahoo Finance Canada
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous...See details»
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference
Vancouver, Canada, November 7, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative …See details»
NervGen Clinical Trial: For Company Founder Punnett, it's Personal …
Jan 26, 2022 · NervGen announced in a press release recently that it intends to test its spinal cord nerve regeneration drug NVG-291 in humans later this year, treating both sub-acute (less …See details»
Bill Adams - CFO at NervGen Pharma - The Org
Bill Adams, CPA, CA, has over 25 years of strategic financial management experience that includes mergers and acquisitions, operations and capital markets in both Canada and the …See details»